Company news

AdAlta Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

European Patent for AD-214 granted

June 13, 2022

BIO International Convention presentation

May 31, 2022

AdAlta presentation at Bioshares Biotech Summit

May 9, 2022

Indian patent for AD-214

April 6, 2022

Inhaled AD-214 preclinical program

April 4, 2022

PAC Partners Healthcare Conference - Corporate Presentation

April 4, 2022

$1.6M Second Tranche R&D Cash Flow Loan Received

March 8, 2022

Chinese patent granted for AD-214

March 1, 2022

Change in Director Interest Notice x 4

February 10, 2022

Application for quotation of securities - 1AD

February 6, 2022

Entitlement Offer Results

February 3, 2022

Presentation to Share Cafe Webinar

January 19, 2022

Presentation Conference Schedule - January 2022

January 3, 2022

Entitlement Offer Booklet

December 22, 2021

Reinstatement to Quotation

December 14, 2021

Voluntary Suspension

December 13, 2021

Inhaled AD-214 passes first development milestone

December 8, 2021

AGM presentations & first iCAR-T data

November 28, 2021

Second US patent for AD-214

November 17, 2021

BTB funding transferred to AD-214 inhalation program

October 6, 2021

New pre-clinical data presented at Boston conference

September 26, 2021

Corporate overview and IRD Invest 2021 presentation

September 20, 2021

$4.0M Non-Dilutive Financing with Victorian Government

September 19, 2021

Carina collaboration webinar presentation

August 25, 2021

CAR-T collaboration with Carina Biotech

August 23, 2021

Webinar and presentation on AD-214 strategy

July 19, 2021

AD-214 pathway to IPF efficacy studies

July 18, 2021

AdAlta secures AD-214 resupply

July 1, 2021

R&D Tax Incentive Facility

June 24, 2021

GE Healthcare collaboration advances to next stage

May 23, 2021

AdAlta granted Japanese patent for AD-214

May 18, 2021

Mutiple Dose Part Of Ad-214 Phase I Trial Commenced

April 18, 2021

Investor briefing-AD-214 top line single dose safety results

March 9, 2021

Appendix 4D and Interim Financial Report

February 25, 2021

FDA Orphan Drug Designation for AD-214

February 23, 2021

Phase I HV extension to explore encouraging results

December 13, 2020

AGM Presentation

November 25, 2020

AusBiotech presentation including Phase I status update

October 26, 2020

Investor Presentation - BIO investor forum

October 9, 2020

GE Healthcare collaboration progresses

September 20, 2020

Non-renounceable Rights Issue Offer

August 18, 2020

Placement and Rights Offer

August 10, 2020

Investor presentation including future milestones

July 29, 2020

First participants treated in AD-214 Phase I trial

July 23, 2020

Supportive US FDA pre-IND meeting results for AD-214

July 19, 2020

AdAlta receives approval to commence AD-214 Phase I trial

June 9, 2020

Business update and COVID-19 response

March 30, 2020

Board changes and R&D Tax Incentive advance received

March 26, 2020

Investor Briefing - Strategic Plan

March 2, 2020

AD-214 effective in gold standard pre-clinical animal model

March 1, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 84 decks. Every deck is listed under its year.